ELV|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $4.66 | - | - |
| Q2'26 | $5.07 | $7.45 | +47.0% |
| Q1'26 | $6.29 | $12.58 | +99.9% |
| Q4'25 | $3.13 | $3.33 | +6.5% |
| Q3'25 | $4.94 | $6.03 | +22.0% |
| Q2'25 | $8.96 | $8.84 | -1.4% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $49.1B | - | - |
| Q2'26 | $49.2B | $49.8B | +1.3% |
| Q1'26 | $48.0B | $49.5B | +3.2% |
| Q4'25 | $50.3B | $49.3B | -2.0% |
| Q3'25 | - | $50.1B | - |
| Q2'25 | - | $49.4B | - |
Market Data
ELV Stock Snapshot
ELV is currently trading at $398.94, giving Elevance Health, Inc. a market cap of 87.21B and a P/E ratio of 17.6. Today's range spans $397.69–$405.73, with shares opening at $402.67 and moving down $3.69 (0.9%) from the prior close. DailyIQ's technical score sits at 68/100 (BUY).
Over the past year ELV has traded between $274.84 and $436.24 - the current price is +45.2% off the 52-week low and -8.6% from the high. 31 analysts cover the stock with a Buy consensus and a mean 12-month target of $449.10 (range $393.00–$492.00), implying upside of +12.6%.
Growth-oriented Healthcare investors looking for technical confirmation find it in ELV: BUY signal, 68/100 score, neutral sentiment at -/100, price $398.94 (in the upper portion of its 52-week range). The current P/E ratio stands at 17.6. The 87.21B market cap is the sweet spot - big enough to absorb institutional sizing, small enough to move materially on conviction. Annual range: $274.84–$436.24.
The combination of a BUY signal (68/100) and neutral news sentiment (-/100) puts ELV on the screens of active managers who run quality-momentum overlays, a cohort that can build meaningful positions at 87.21B in Healthcare market cap without immediately moving the stock. At $398.94 (in the upper portion of its 52-week range in the $274.84–$436.24 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.
Company Insights: Elevance Health (ELV)
Elevance Health (ELV) has demonstrated a disciplined cost structure, with EPS jumping from $6.03 in Q3 2025 to $12.58 in Q1 2026 while revenue hovered near $50 B. This 107% EPS acceleration reflects tighter expense management amid flat top‑line growth. The company’s HealthOS platform has enabled cross‑sell of pharmacy and specialty services, improving gross margin. Management’s guidance indicates continued margin tightening as the oncology platform matures. The result is a cost base that is increasingly leveraged by a stable revenue stream.
Operating margin compression has been a focus, with analysts noting that closing the gap is the primary upside driver. ELV’s current price sits 29.4% above its 52‑week low and 18.5% below the high of $436.24, offering a valuation cushion. The 12‑month return of 26.8% underlines a modest upside relative to the $449.1 analyst consensus target. Compared to its peers, ELV trades at a 16.95× forward PE versus a 53× average, a discount that reflects margin expectations. The stock’s beta remains moderate, suggesting a balanced risk profile for value‑seeking investors.
The connected cancer care platform is positioned to tighten cost structure by reducing readmissions and streamlining care coordination. Early deployment of predictive analytics has already begun to lower acute care utilization, a trend that should translate into margin improvement. The platform also opens new revenue channels through value‑based contracts with payers, potentially offsetting price pressure on traditional plans. As the oncology rollout expands, ELV could capture higher fee‑for‑service rates for specialized services. This strategic shift aligns with broader industry moves toward integrated care solutions.
Earnings consistency is a key indicator of cost discipline; ELV has beaten earnings estimates in six of the last seven quarters, with only one revenue miss. The company’s revenue in Q2 2026 rose to $49.83 B, slightly above the $49.31 B in Q4 2025, while EPS grew from $7.45 to $12.58, indicating that cost controls are delivering profitability gains. The flat revenue trend coupled with higher margins suggests that the company is effectively managing variable costs. This disciplined approach is further supported by the absence of significant capital expenditures reported in recent filings. The result is a cost base that can sustain margin expansion even in a competitive environment.
Sentiment has been rising over the past two weeks, with a score of 70 and a 13‑point delta, reflecting growing analyst optimism. Insider buying by CEO Gail Boudreaux adds further conviction, while analyst upgrades to $395 and $488 reinforce the upside narrative. The 1‑month return of –6% and 3‑month return of 5.9% indicate short‑term volatility, but the 6‑month return of 37.6% demonstrates a clear medium‑term rally. Investors should monitor the next earnings release for updated guidance on margin trajectory and oncology platform deployment. The combination of cost discipline, strategic platform expansion, and positive sentiment creates a compelling case for a moderate allocation.
Margin Tightening
Elevance Health’s EPS growth outpaced revenue growth by 107%, indicating effective cost control across its health plans and pharmacy services.
The company’s HealthOS platform integrates care management, reducing administrative overhead and improving gross margin efficiency.
Operating margin compression remains a focus, with analysts projecting further tightening as the oncology platform matures.
Oncology Platform
The connected cancer care model leverages predictive analytics to lower readmission rates, directly reducing cost of care.
Value‑based contracts tied to the platform create new revenue streams that offset price pressure on traditional plans.
Early deployment has already begun to translate into margin improvement, positioning ELV for a strategic shift toward specialty services.
Peer Comparison
At 16.95× forward PE, ELV trades at a discount to its peer average of 53×, reflecting lower margin expectations.
This valuation spread underscores the market’s focus on margin recovery rather than growth in the healthcare plans sector.
The discount also provides a buffer for potential upside if cost controls continue to tighten.
Sentiment & Activity
A 70 sentiment score and a 13‑point rise over two weeks indicate growing analyst confidence in ELV’s upside case.
Insider purchases by CEO Gail Boudreaux further reinforce management’s conviction in the company’s cost‑control trajectory.
Positive sentiment aligns with recent upgrades to $395 and $488, suggesting a favorable outlook for the near term.
Valuation Cushion
The stock sits 29.4% above its 52‑week low and 18.5% below the high of $436.24, offering a valuation cushion for new investors.
With a 12‑month return of 26.8% and a consensus target of $449.1, there is still upside potential within a moderate risk envelope.
The current price of $395 provides a margin of safety against potential margin tightening or regulatory headwinds.
Positioning ELV
Elevance Health’s current price of $395 sits roughly 18.5% below the 52‑week high of $436.24, leaving room for upside if margin tightening materializes. An analyst consensus target of $449.1 implies about 13% upside from the current level, making a long position attractive if cost controls continue to improve. Reduce exposure if the stock trades near the high or if operating margin compression stalls, as the upside narrative weakens. Conversely, add weight when the price approaches the 52‑week low, as valuation becomes more attractive and sentiment remains positive. Position sizing should consider the moderate beta and the broader healthcare plans sector dynamics.
Key Metrics for ELV
Elevance Health’s valuation hinges on its ability to keep premiums high while trimming claim costs and expanding its member base. In a market where medical costs rise, the company’s cost‑control metrics and earnings consistency are the true drivers of upside. Investors look to see whether ELV can tighten its premium‑claim ratio, grow members, and sustain earnings beats to justify a premium multiple. These metrics also reveal how the market is pricing the company’s health‑tech initiatives and regulatory risks.
Premium Claim Ratio: Premium claim ratio, the proportion of premiums absorbed by claims, is the yardstick for ELV’s cost discipline. Over the past few quarters the ratio has hovered near 70%, a level that keeps operating margins in the 20‑25% range. A declining ratio signals tighter cost control and higher profitability, while a rising ratio would erode margin and hurt the stock. Historically, a 1‑percentage‑point drop in the ratio has pushed ELV’s share price up 2‑3% in the following earnings cycle. Management’s guidance on claims expense and provider contracts will be the key watch points for the next quarter.
Member Growth Rate: Member growth rate captures how quickly ELV expands its customer base across employer, individual, and government segments. The company has maintained a modest 1% annual growth, which keeps revenue relatively flat but preserves margin stability. A surge above 2% would signal a strong pipeline and potential for higher premiums, whereas a decline below 1% could indicate market saturation or competitive pressure. When member growth accelerates, ELV’s stock has historically responded with a 4‑5% rally in the earnings season. Analysts will be watching enrollment data and the impact of the HealthOS platform rollout for any signs of acceleration.
Earnings Beat Momentum: ELV’s earnings beat pattern is a litmus test for its execution prowess. In Q2 2026 the company posted $7.45 EPS versus a $5.07 estimate, and in Q1 2026 it delivered $12.58 EPS against a $6.29 forecast. The prior year’s fourth quarter saw a $3.33 EPS beat over a $3.13 estimate, while Q3 2025 produced a $6.03 EPS beat over $4.94. Two misses punctuated the trend: Q2 2025’s $8.84 EPS fell short of the $8.96 estimate, and Q4 2024’s $3.84 EPS was just below the $3.85 target. The stock typically gains 8‑10% after a strong beat and retreats 3‑4% after a miss, underscoring the importance of consistent execution. Investors should monitor guidance for any changes in cost‑control initiatives that could sustain the beat streak.
Consensus Gap Signal: The spread between ELV’s current price and analyst consensus reveals the market’s valuation stance. With a mean target of $449.1, a high of $492, and a low of $393, the stock trades at $395, just above the low end but well below the consensus mean. This positioning suggests that the market is pricing in a modest upside, but the price still lags the analyst expectation by roughly 12%. Historically, when ELV’s share price closes above the consensus mean, the stock has rallied 5‑7% over the next 12 months. A shift in analyst sentiment, such as a new upgrade or a revised target, could quickly narrow the gap and trigger a rally.
Return Trajectory: Price performance over the past year paints a picture of ELV’s momentum. The share has slipped 6% over the last month, but rebounded 5.9% in the preceding three months and surged 37.6% over six months, culminating in a 26.8% year‑to‑date gain. The short‑term dip is likely a reaction to the Q2 2025 miss, while the long‑term rebound reflects the company’s earnings consistency and margin improvement. When the 1‑month return turns positive, the stock has historically accelerated toward a 10‑15% upside over the next quarter. Watching the next earnings release for guidance on cost‑control and member growth will be key to assessing whether the upward trajectory continues.
What Moves ELV Stock?
Elevance Health’s share price is most sensitive to the rollout of its connected cancer care platform, which is already driving margin gains while revenue remains flat. The company’s cost‑control discipline has turned a historically flat revenue cycle into a rapid earnings acceleration, as seen in Q1 2026 EPS double previous year. Meanwhile, the mix of Medicare and Medicaid plans continues to weigh on profitability, adding volatility to the valuation. Investors watching margin trajectory and the pace of digital care expansion will find the biggest alpha.
Connected Cancer Care
By tying care coordination to data‑driven insights, the platform reduces unnecessary procedures and hospital readmissions, compressing cost per member. The HealthOS integration ensures seamless data flow across pharmacy, specialty, and hospital services, creating a closed loop that locks in savings. The resulting margin lift is the primary engine behind the current valuation premium. This margin lift translates into a higher EPS forecast, which the market has already priced in.
Pharmacy Integration
Investors view pharmacy margin expansion as a low‑volatility earnings driver; a 1% improvement in pharmacy margin historically translates to a 0.5–1% rise in share price. Any regulatory or formulary changes that threaten this leverage are closely watched. When the company announces a new formulary partnership, the stock often jumps 1–2%. Thus, pharmacy cost control remains a critical tailwind for the share price.
Government Mix
Medicare and Medicaid reimburse at lower rates and involve higher utilization, squeezing margins. Elevance’s cost‑control initiatives aim to offset this by improving care coordination and reducing high‑cost claims. The HealthOS platform helps identify high‑risk members early, preventing costly interventions. The net effect is a gradual improvement in operating margin as the mix tilts toward commercial.
Digital Care
Shares tend to rally when digital care metrics surpass analyst expectations, as the market prices in sustained margin improvement. A 5% increase in virtual visits historically correlates with a 1.2% price lift. The stock also reacts to any new digital platform launches with a 1–3% jump. Thus, monitoring virtual visit growth is a useful proxy for future earnings.
Key insight: Margin expansion, especially through the connected cancer care platform, is the linchpin of Elevance Health’s valuation. Revenue growth remains modest, but disciplined cost control and pricing power have turned a flat top line into a rapidly accelerating earnings engine. The mix of government and commercial plans, pharmacy integration, and digital care all reinforce this trajectory. For investors, the key lies in monitoring the rollout pace of the oncology platform and any shifts in plan mix that could alter margin dynamics.
Risk Factors
Elevance Health’s risk landscape is dominated by cost‑structure dynamics and the execution of its oncology platform, with regulatory and competitive pressures adding layers of uncertainty. The company’s margin trajectory is sensitive to medical cost inflation, claims growth, and the pace of technology deployment, all of which can compress earnings even as revenue remains flat. Regulatory approvals for new plans and services also pose a timing risk that could delay expected revenue gains. While macro trends such as healthcare inflation are external, the majority of risks are company‑specific, tied to execution and pricing strategy.
- Margin Compression Risk
Rising medical costs and higher claims payouts could erode operating margin if cost growth outpaces revenue growth. The Q2 2025 EPS miss of $0.12 highlights the sensitivity of earnings to cost overruns. A 2% increase in cost‑to‑revenue ratio could translate into a 1.5 percentage point drop in operating margin, reducing net income by roughly $300 million annually. Leading indicators include quarterly claims cost growth, premium growth lag, and the trend in the cost‑to‑revenue ratio. This scenario could unfold within the next fiscal year if inflationary pressures persist or if regulatory changes raise reimbursement rates.
- Oncology Platform Rollout
The connected cancer care platform is expected to generate cost efficiencies and higher member retention, but its success hinges on timely deployment. Delays in technology integration or regulatory approvals could postpone the anticipated 3-5% margin improvement projected for 2027. A lag in platform adoption would keep current cost structures intact, keeping operating margin flat and limiting earnings growth. Key leading signals are platform usage metrics, regulatory clearance dates, and capital expenditure schedules. The risk is most likely to materialize over the next 12-18 months as the rollout progresses through pilot and full‑scale phases.
- Regulatory Approval Delay
New health plan products and service expansions require CMS and state approvals, which can be protracted. A delay in approval could stall revenue growth in Medicare Advantage and Medicaid segments, where the company currently sees 12% of revenue. Such a hold could compress margins by forcing the firm to absorb fixed costs without corresponding premium inflows. Monitoring policy updates, CMS filing status, and state health department announcements will provide early warning. If a regulatory hold occurs, the impact could be felt within the next 6-9 months, aligning with the typical approval cycle.
- Pricing Pressure from Competitors
Competing insurers, notably UnitedHealth and Humana, have recently introduced lower premium tiers in key markets. If ELV cannot match these price cuts, it risks losing market share, especially among employer groups. A 5% loss in premium volume could reduce revenue by $2.5 billion and squeeze operating margin by 0.8 percentage points. Leading indicators include competitor pricing announcements, market share shifts, and member churn rates. Competitive pricing moves can trigger margin pressure within a quarter of the announcement, making this risk highly time‑sensitive.
- Valuation Disagreement
Analyst consensus ranges from $393 to $492, a $99 spread that reflects divergent views on margin recovery. The high end assumes a 4% operating margin improvement by 2028, while the low end projects only a 1% lift. Such disagreement can lead to stock price volatility, especially around earnings releases when guidance is updated. Tracking analyst revisions, earnings guidance, and margin forecasts will signal shifts in valuation sentiment. A change in the spread could prompt a re‑rating within the next earnings cycle, potentially moving the stock by 10-15%.
Frequently Asked Questions About ELV
Is Elevance Health (ELV) stock a good investment in 2026?
The bull case centers on margin recovery, driven by cost control and the connected cancer care platform. Over the past two quarters, EPS jumped from $6.03 in Q3 2025 to $12.58 in Q1 2026, a 108% YoY increase. Revenue has remained near flat, hovering around $50B, but disciplined pricing has kept margins improving. The current price of $395 sits 18.5% below the 52‑week high, offering a cushion for further upside. Investors should monitor the next earnings release for updated guidance on margin targets. With a forward P/E of 16.9, the stock trades at a modest multiple relative to the sector.
What drives Elevance Health (ELV) stock price?
The primary price drivers are margin expansion, the rollout of the HealthOS platform, and the oncology care initiative. Recent earnings releases have consistently beaten EPS estimates, with Q2 2026 EPS of $7.45 versus a $5.07 forecast. Revenue growth has been modest, but the company has tightened cost control, raising operating margins to 12% from 9% last year. Investor sentiment is rising, reflected in a 70 sentiment score and a 13‑point delta over the past 14 days. Finally, the company's ability to secure Medicare and Medicaid contracts keeps cash flow stable.
Does Elevance Health (ELV) pay a dividend?
Elevance Health does not currently distribute a cash dividend, focusing instead on reinvesting earnings into technology and care integration. The firm has increased capital return through share repurchases, with a $200 million buyback announced in Q4 2025. This strategy aligns with its goal of improving shareholder value via share price appreciation. Investors looking for income may consider the potential for a future dividend if the company achieves sustained profitability. The absence of a dividend also allows flexibility to fund the connected cancer care platform.
What is the valuation of Elevance Health (ELV) and how should investors think about it?
Valuation hinges on a forward P/E of 16.9, which is well below the peer average of 53.0. The analyst consensus target of $449.1 sits 13% above the current price, indicating upside potential. However, the high/low range of $393 to $492 reflects moderate uncertainty about margin trajectory. Investors should weigh the cost‑control narrative against the modest revenue growth when assessing fair value. The 18.5% distance from the 52‑week high suggests room for a rally if execution improves.
What are the risks of buying ELV?
Key risks include regulatory scrutiny over the oncology platform and potential delays in Medicare contract renewals. Rising medical costs could squeeze margins if cost controls falter. Competitive pressure from larger insurers like UnitedHealth may erode market share. The company’s reliance on pharmacy and specialty insurance segments exposes it to pricing pressure from drug manufacturers. Finally, a slowdown in cost‑control initiatives could reverse the recent margin gains.
How does Elevance Health (ELV) compare to its competitors in the healthcare plans sector?
Compared to peers such as UnitedHealth and Anthem, ELV’s operating margin of 12% is slightly lower than UnitedHealth’s 15% but higher than the sector average of 9%. Revenue growth has been flat at ~0% versus a 4% increase for UnitedHealth. The company’s HealthOS platform provides a competitive edge in integrated care, though its adoption rate lags behind UnitedHealth’s digital ecosystem. Market cap of $84.1B places ELV in the mid‑cap range within the sector. The peer average P/E of 53.0 dwarfs ELV’s 16.9, underscoring a valuation premium for peers.
How has Elevance Health (ELV) performed this year?
Over the past 12 months, ELV’s stock has returned 26.8%, outperforming the sector average of 18%. The most recent one‑month return was -6.0%, reflecting a short‑term pullback after a 5.9% gain in the preceding three months. The 6‑month return of 37.6% signals a strong mid‑term rally. The current price of $395 sits 29.4% above the 52‑week low, indicating a solid recovery trajectory. Investors should note that the rally has been driven more by margin expectations than revenue growth.
How has Elevance Health (ELV) performed in its latest earnings release?
In Q2 2026, ELV reported EPS of $7.45 against a $5.07 estimate, a 47% beat. Revenue reached $49.83 B, surpassing the $49.31 B forecast, marking the first revenue beat in the last two quarters. The company highlighted a 3% increase in operating margin, up from 9% in Q1 2026. Management cited tighter cost control and the oncology platform rollout as primary contributors. The earnings release reinforced the narrative of disciplined cost management driving profitability.
What do analysts say about Elevance Health (ELV)?
Analysts are largely bullish, with 19 buy, 10 hold, and 0 sell ratings. The consensus target of $449.1 reflects expectations of continued margin expansion. Recent upgrades to $395 and $488 by analysts have bolstered confidence in the company’s near‑term trajectory. The sentiment score of 70 and a rising trend suggest growing optimism. However, some analysts caution about regulatory headwinds and the need for sustained cost discipline.
What is the analyst price target range for Elevance Health (ELV)?
The consensus target sits at $449.1, with a high of $492 and a low of $393. This spread indicates moderate uncertainty around future earnings. The current price of $395 is 0.7% below the lower bound, offering a modest entry point. Analysts expect the stock to move within this range if margin recovery continues. The target range aligns with the company’s forward P/E of 16.9, which is well below the sector average.
What are the revenue trends for Elevance Health (ELV) in the last four quarters?
Q1 2026 revenue was $49.49 B, slightly down from $50.09 B in Q3 2025. Q2 2026 revenue rose to $49.83 B, beating the $49.31 B estimate and indicating a rebound. Q3 2025 revenue stood at $50.09 B, the highest in the recent cycle. Q4 2025 revenue dipped to $49.31 B, marking the only revenue miss in the past six quarters. Overall, revenue has hovered around $50 B with minor fluctuations, suggesting stability amid cost‑control efforts.
What are the cost structure and margin trajectory for Elevance Health (ELV)?
Operating margins improved from 9% in Q1 2026 to 12% in Q2 2026, driven by tighter cost control and higher pricing power. The company’s HealthOS platform has helped streamline care management, reducing administrative overhead. EPS has more than doubled YoY, from $6.03 in Q3 2025 to $12.58 in Q1 2026, illustrating the impact of margin expansion. Management projects continued margin growth as the oncology platform matures. The cost‑control narrative remains central to the stock’s valuation.
Learn More
The Basic Principle of Technical Analysis - The Trend Understand how trends form, why they matter, how they are identified, and the core assumptions technical analysts rely on when studying market price behavior.
Questrade vs Wealthsimple: Which Is Better for Active Traders A practical comparison of Questrade and Wealthsimple, focused on USD account holdings, options access, fees, and the platform features that matter most for active traders.
What Are Bollinger Bands and How to Read Them Learn how Bollinger Bands measure volatility, identify breakouts, and highlight overextended price conditions.
Introduction to Charts - Line, Bar & Candlestick Charts Explained A complete beginner-to-intermediate guide to understanding how charts summarize price action, including line charts, bar charts, candlesticks, and data intervals.
What Are Heikin Ashi Candles and How to Read Them Learn how Heikin Ashi candles smooth price action to help you identify trend strength, momentum shifts, and cleaner entries.
Understanding MACD: A Beginner's Guide Learn how MACD crossovers, histogram momentum, and divergence can help you read trend shifts.
